Literature DB >> 8318173

Apparent HIV-1 glycoprotein reactivity on western blot in uninfected blood donors.

D S Healey1, W V Bolton.   

Abstract

OBJECTIVES: To investigate samples with 'false-positive' reactivity to HIV-1 glycoproteins on Western blot (WB).
DESIGN: Samples from 13 blood donors with glycoprotein reactivity were examined for serological evidence of HIV infection and followed-up where possible.
METHODS: Samples were tested for anti-HIV-1, HIV-1 p24 antigen, anti-HIV-2 and anti-HTLV-1. Reactivity to multimeric, monomeric, and deglycosylated gp41 was determined, as was the ability of recombinant gp160 (rgp160) to inhibit reactivity to multimeric gp41.
RESULTS: Serology and follow-up failed to confirm HIV infection in any of the donors. All samples reacted to multimeric gp41, and eight out of the 13 reacted to deglycosylated gp41. Reactivity on a commercial WB was inhibited by rgp160.
CONCLUSION: Apparent reactivity to HIV-1 glycoprotein may occur in individuals with no other serological evidence of HIV infection. Reactivity to different forms of gp41 and inhibition by rgp160 suggested that the observed WB reactivity may be due to cross-reactivity with gp41 rather than to a co-migrating contaminant.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8318173     DOI: 10.1097/00002030-199305000-00007

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  3 in total

Review 1.  Laboratory tests for detection of human immunodeficiency virus type 1 infection.

Authors:  N F Nuwayhid
Journal:  Clin Diagn Lab Immunol       Date:  1995-11

2.  Anti-human immunodeficiency virus type 1 antibodies of noninfected subjects are not related to autoantibodies occurring in systemic diseases.

Authors:  R Kämmerer; P Bürgisser; P C Frei
Journal:  Clin Diagn Lab Immunol       Date:  1995-07

3.  The evaluation of a rapid in situ HIV confirmation test in a programme with a high failure rate of the WHO HIV two-test diagnostic algorithm.

Authors:  Derryck B Klarkowski; Joseph M Wazome; Kamalini M Lokuge; Leslie Shanks; Clair F Mills; Daniel P O'Brien
Journal:  PLoS One       Date:  2009-02-06       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.